NASDAQ:VRCA Verrica Pharmaceuticals (VRCA) Stock Price, News & Analysis $5.30 0.00 (0.00%) As of 09/4/2026 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOwnershipSEC Filings About Verrica Pharmaceuticals Stock (NASDAQ:VRCA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get VRCA alerts:Sign Up Key Stats Today's Range$5.25▼$5.5350-Day Range$4.68▼$6.6252-Week Range$3.28▼$9.82Volume12,187 shsAverage Volume107,463 shsMarket Capitalization$91.05 millionP/E RatioN/ADividend YieldN/APrice Target$12.67Consensus RatingHold Company Overview Verrica Pharmaceuticals Inc. is a clinical‐stage biopharmaceutical company focused on the development and commercialization of topical therapies for dermatological conditions. Its lead investigational product, VP-102, is a standardized formulation of cantharidin in a pre-measured applicator designed to treat molluscum contagiosum and common warts. Verrica’s approach emphasizes consistency of dosing and patient convenience, aiming to improve upon off‐label use of existing treatments. Beyond VP-102, Verrica is advancing VP-103, a next‐generation topical candidate intended to optimize tolerability while maintaining efficacy against viral skin lesions. The company conducts its clinical trials primarily in the United States and has engaged with regulatory authorities in Europe to support potential future filings. Verrica collaborates with contract research organizations and academic partners to execute its development programs and gather data on safety and efficacy. Founded in 2020 as a strategic spin-out from Aclaris Therapeutics, Verrica is headquartered in West Chester, Pennsylvania. The company’s management team brings deep expertise in dermatology drug development, clinical operations and commercial strategy. As Verrica moves toward potential product approvals, it aims to address significant unmet needs in pediatric and adult dermatology markets.AI Generated. May Contain Errors. Read More Verrica Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks74th Percentile Overall ScoreVRCA MarketRank™: Verrica Pharmaceuticals scored higher than 74% of companies evaluated by MarketBeat, and ranked 177th out of 910 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingHold Consensus RatingVerrica Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.40, and is based on no strong buy ratings, 3 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialVerrica Pharmaceuticals has a consensus price target of $12.67, representing about 139.0% upside from its current price of $5.30.Amount of Analyst CoverageVerrica Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.Read more about Verrica Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Verrica Pharmaceuticals are expected to grow in the coming year, from ($2.25) to ($2.00) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Verrica Pharmaceuticals is -3.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Verrica Pharmaceuticals is -3.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVerrica Pharmaceuticals has a P/B Ratio of 3.42. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Verrica Pharmaceuticals' valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.33% of the float of Verrica Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverVerrica Pharmaceuticals has a short interest ratio ("days to cover") of 5.16.Change versus previous monthShort interest in Verrica Pharmaceuticals has recently decreased by 6.39%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldVerrica Pharmaceuticals does not currently pay a dividend.Dividend GrowthVerrica Pharmaceuticals does not have a long track record of dividend growth. News and Social Media1.3 / 5News SentimentN/A Search Interest1 people have searched for VRCA on MarketBeat in the last 30 days. MarketBeat Follows3 people have added Verrica Pharmaceuticals to their MarketBeat watchlist in the last 30 days. Company Ownership4.8 / 5Insider TradingAcquiring Shares Cluster Insider Buying2 insiders have purchased shares of Verrica Pharmaceuticals in the last three months. Multiple insiders buying is a strong bullish signal.Net Insider BuyingOver the last three months, insiders have purchased a net $55,160.00 in company stock, which represents 0.0606% of the company's market cap.Insider Buying vs. Insider SellingIn the past three months, Verrica Pharmaceuticals insiders have bought more of their company's stock than they have sold. Specifically, they have bought $55,160.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders52.90% of the stock of Verrica Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions42.45% of the stock of Verrica Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Verrica Pharmaceuticals' insider trading history. Receive VRCA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Verrica Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. VRCA Stock News HeadlinesVerrica Pharmaceuticals (NASDAQ:VRCA) Coverage Initiated at Lake Street CapitalAugust 29, 2026 | americanbankingnews.comVerrica Pharmaceuticals Announces Completion of Enrollment in First Pivotal Phase 3 Trial (COVE-2) Evaluating YCANTH® for the Treatment of Common Warts, with Topline Data ...August 27, 2026 | finance.yahoo.comThe REAL Reason Trump is Invading IranFor a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Because my research has led me to believe we’re risking World War 3 with Iran for a completely different reason.September 7 at 1:00 AM | Banyan Hill Publishing (Ad)Verrica Pharmaceuticals Announces Completion of Enrollment in First Pivotal Phase 3 Trial (COVE-2) Evaluating YCANTH® for the Treatment of Common Warts, with Topline Data Expected Q1 2027August 27, 2026 | globenewswire.comVerrica Pharmaceuticals (NASDAQ:VRCA) CMO Noah Rosenberg Buys 4,200 SharesAugust 19, 2026 | insidertrades.comVerrica (VRCA) Q2 2026 Earnings Call TranscriptAugust 14, 2026 | finance.yahoo.comVerrica Pharmaceuticals Inc. (VRCA) Q2 2026 Earnings Call TranscriptAugust 7, 2026 | seekingalpha.comVerrica Pharmaceuticals Closes Credit Facility For Up To $27.5 Million in Non-Dilutive Growth CapitalAugust 6, 2026 | finance.yahoo.comSee More Headlines VRCA Stock Analysis - Frequently Asked Questions How have VRCA shares performed this year? Verrica Pharmaceuticals' stock was trading at $8.31 at the beginning of the year. Since then, VRCA shares have decreased by 36.2% and is now trading at $5.30. How were Verrica Pharmaceuticals' earnings last quarter? Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) announced its earnings results on Tuesday, May, 12th. The company reported ($0.41) earnings per share for the quarter, topping analysts' consensus estimates of ($0.59) by $0.18. The company earned $5.02 million during the quarter, compared to analysts' expectations of $4.51 million. Verrica Pharmaceuticals had a negative net margin of 102.84% and a negative trailing twelve-month return on equity of 407.11%. Read the conference call transcript. When did Verrica Pharmaceuticals' stock split? Verrica Pharmaceuticals's stock reverse split on Friday, July 25th 2025.A 1-10 reverse split was announced. The number of shares owned by shareholders was adjusted after the market closes on Thursday, July 24th 2025. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. When did Verrica Pharmaceuticals IPO? Verrica Pharmaceuticals (VRCA) raised $75 million in an initial public offering (IPO) on Friday, June 15th 2018. The company issued 5,000,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, Jefferies and Cowen acted as the underwriters for the IPO. How do I buy shares of Verrica Pharmaceuticals? Shares of VRCA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Verrica Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Verrica Pharmaceuticals investors own include Meta Platforms (META), Paycom Software (PAYC), Walt Disney (DIS), uniQure (QURE), Centrus Energy (LEU) and Clean Energy Fuels (CLNE). Company Calendar Last Earnings5/12/2026Today9/07/2026Next Earnings (Estimated)11/13/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (3d) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 As of 3 days ago, VRCA's financial health entered the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:VRCA CIK1660334 Webwww.verrica.com Phone(434) 453-3300FaxN/AEmployees40Year Founded2013Price Target and Rating Average Price Target for Verrica Pharmaceuticals$12.67 High Price Target$17.00 Low Price Target$9.00 Potential Upside/Downside+139.0%Consensus RatingHold Rating Score (0-4)2.40 Research Coverage5 Analysts Profitability EPS (Trailing Twelve Months)($1.67) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$17.89 million Net Margins-102.84% Pretax Margin-102.84% Return on Equity-407.11% Return on Assets-70.17% Debt Debt-to-Equity Ratio0.18 Current Ratio1.45 Quick Ratio1.33 Sales & Book Value Annual Sales$35.58 million Price / Sales2.56 Cash FlowN/A Price / Cash FlowN/A Book Value$1.55 per share Price / Book3.42Miscellaneous Outstanding Shares17,180,000Free Float8,091,000Market Cap$91.05 million OptionableNo Data Beta1.49 Social Links 7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.Get This Free Report This page (NASDAQ:VRCA) was last updated on 9/7/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...Investors Alley | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Verrica Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Verrica Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free VRCA Stock Alerts